| Review of WADA prohibited substances: limited evidence for performance-enhancing effects JAAC Heuberger, AF Cohen Sports Medicine 49 (4), 525-539, 2019 | 122 | 2019 |
| Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk–benefit JAAC Heuberger, JM Cohen Tervaert, FML Schepers, ADB Vliegenthart, ... British journal of clinical pharmacology 75 (6), 1406-1421, 2013 | 106 | 2013 |
| Effects on spasticity and neuropathic pain of an oral formulation of Δ9-tetrahydrocannabinol in patients with progressive multiple sclerosis G van Amerongen, K Kanhai, AC Baakman, J Heuberger, E Klaassen, ... Clinical therapeutics 40 (9), 1467-1482, 2018 | 94 | 2018 |
| Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short-and long-term pharmacokinetics JAAC Heuberger, Z Guan, OO Oyetayo, L Klumpers, PD Morrison, ... Clinical pharmacokinetics 54, 209-219, 2015 | 90 | 2015 |
| When is protein binding important? J Heuberger, S Schmidt, H Derendorf Journal of pharmaceutical sciences 102 (9), 3458-3467, 2013 | 90 | 2013 |
| Effects of erythropoietin on cycling performance of well trained cyclists: a double-blind, randomised, placebo-controlled trial JAAC Heuberger, JI Rotmans, P Gal, FE Stuurman, J van't Westende, ... The Lancet Haematology 4 (8), e374-e386, 2017 | 75 | 2017 |
| Accelerated development of the dual orexin receptor antagonist ACT‐541468: integration of a microtracer in a first‐in‐human study C Muehlan, J Heuberger, PE Juif, M Croft, J van Gerven, J Dingemanse Clinical Pharmacology & Therapeutics 104 (5), 1022-1029, 2018 | 68 | 2018 |
| DNL 104, a centrally penetrant RIPK 1 inhibitor, inhibits RIP 1 kinase phosphorylation in a randomized phase I ascending dose study in healthy volunteers HW Grievink, JAAC Heuberger, F Huang, R Chaudhary, WAJ Birkhoff, ... Clinical Pharmacology & Therapeutics 107 (2), 406-414, 2020 | 56 | 2020 |
| Repeatability and predictive value of lactate threshold concepts in endurance sports JAAC Heuberger, P Gal, FE Stuurman, WAS de Muinck Keizer, ... PloS one 13 (11), e0206846, 2018 | 56 | 2018 |
| Indanes—properties, preparation, and presence in ligands for G protein coupled receptors M Vilums, J Heuberger, LH Heitman, AP IJzerman Medicinal Research Reviews 35 (6), 1097-1126, 2015 | 46 | 2015 |
| The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients … H Kletzl, A Marquet, A Günther, W Tang, J Heuberger, GJ Groeneveld, ... Neuromuscular Disorders 29 (1), 21-29, 2019 | 44 | 2019 |
| In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms SKB Sy, ME Beaudoin, L Zhuang, KI Löblein, C Lux, M Kissel, R Tremmel, ... Journal of Antimicrobial Chemotherapy 71 (7), 1866-1880, 2016 | 44 | 2016 |
| Acute effects of riluzole and retigabine on axonal excitability in patients with amyotrophic lateral sclerosis: a randomized, double‐blind, placebo‐controlled, crossover trial MO Kovalchuk, JAAC Heuberger, BTHM Sleutjes, D Ziagkos, ... Clinical Pharmacology & Therapeutics 104 (6), 1136-1145, 2018 | 42 | 2018 |
| Tolerance to opioid‐induced respiratory depression in chronic high‐dose opioid users: a model‐based comparison with opioid‐naive individuals MH Algera, E Olofsen, L Moss, RL Dobbins, M Niesters, M van Velzen, ... Clinical Pharmacology & Therapeutics 109 (3), 637-645, 2021 | 36 | 2021 |
| Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: randomized, placebo‐controlled, double‐blind phase I … MFJM Vissers, JAAC Heuberger, GJ Groeneveld, J Oude Nijhuis, ... Clinical and translational science 15 (8), 2010-2023, 2022 | 35 | 2022 |
| LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson's disease D Jennings, S Huntwork‐Rodriguez, MFJM Vissers, VM Daryani, D Diaz, ... Movement Disorders 38 (3), 386-398, 2023 | 28 | 2023 |
| EpoR stimulates rapid cycling and larger red cells during mouse and human erythropoiesis D Hidalgo, J Bejder, R Pop, K Gellatly, Y Hwang, S Maxwell Scalf, ... Nature Communications 12 (1), 7334, 2021 | 25 | 2021 |
| Pharmacokinetic modeling and dose selection in a randomized, double-blind, placebo-controlled trial of a human recombinant alkaline phosphatase in healthy volunteers E Peters, JAAC Heuberger, R Tiessen, A van Elsas, R Masereeuw, ... Clinical Pharmacokinetics 55, 1227-1237, 2016 | 25 | 2016 |
| Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: a placebo-controlled crossover study in healthy volunteers and opioid … LM Moss, MH Algera, R Dobbins, F Gray, S Strafford, A Heath, ... PLoS One 17 (1), e0256752, 2022 | 19 | 2022 |
| A Markov Chain Model to Evaluate the Effect of CYP3A5 and ABCB1 Polymorphisms on Adverse Events Associated with Tacrolimus in Pediatric Renal … SKB Sy, J Heuberger, S Shilbayeh, DJ Conrado, H Derendorf The AAPS journal 15, 1189-1199, 2013 | 19 | 2013 |
